The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
Abstract
Objective: The interleukin‐6 pathway is up‐regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of 10 patients with relapsing/refractory GCA, TA, or PMR treated with tocilizumab (TCZ). Methods: Patients with GCA (n = 7), TA (n = 2), and PMR (n = 1) received TCZ. Seven subjects had failed at least 1 second‐line agent. The outcomes evaluated were symptoms of disease activity, inflammatory markers, ability to taper glucocorticoids, and cross‐sectional imaging when indicated clinically. Results: The mean followup time of this cohort since diagnosis was 27 months (range 16–60 months). The patients were treated with TCZ for a mean period of 7.8 months (range 4–12 months). Before TCZ therapy, the patients experienced an average of 2.4 flares/year. All patients entered and maintained clinical remission during TCZ therapy. The mean daily prednisone dosages before and after TCZ initiation were 20.8 mg/day (range 7–34.3 mg/day) and 4.1 mg/day (range 0–10.7 mg/day), respectively (P = 0.0001). The mean erythrocyte sedimentation rate declined from 41.5 mm/hour (range 11–68 mm/hour) to 7 mm/hour (range 2.2–11.3 mm/hour; P = 0.0001). The adverse effects of TCZ included mild neutropenia (n = 4) and transaminitis (n = 4). One patient flared 2 months after TCZ discontinuation. An autopsy on 1 patient who died from a postoperative myocardial infarction following elective surgery revealed persistent vasculitis of large and medium‐sized arteries. Conclusion: TCZ therapy led to clinical and serologic improvement in patients with refractory/relapsing GCA, TA, or PMR. The demonstration of persistent large‐vessel vasculitis at autopsy of 1 patient who had shown a substantial response requires close scrutiny in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis
Arend, W. P., Michel, B. A., Bloch, D. A., Hunder, G. G., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330811 · Cited by 2,267
Kerr, G. S., Hallahan, C. W., Giordano, J. M., Leavitt, R. Y., Fauci, A. S., Rottem, M., & Hoffman, G. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00004 · Cited by 1,625
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4 + T Cells
O’Shea, J. J., & Paul, W. E. (2010) · Science · doi:10.1126/science.1178334 · Cited by 1,336
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
EULAR recommendations for the management of large vessel vasculitis
Mukhtyar, C. B., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W. L., Hauser, T., Hellmich, B., Jayne, D. R. W., Kallenberg, C. G. M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088351 · Cited by 673
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Cited by
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Villiger, P. M., Adler, S., Kuchen, S., Wermelinger, F., Dan, D., Fiege, V., Bütikofer, L., Seitz, M., & Reichenbach, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00560-2 · Cited by 577
Immune mechanisms in medium and large-vessel vasculitis
Weyand, C. M., & Goronzy, J. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.161 · Cited by 412
Giant-Cell Arteritis and Polymyalgia Rheumatica
Weyand, C. M., & Goronzy, J. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1214825 · Cited by 410
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40044 · Cited by 394
Grayson, P. C., Alehashemi, S., Bagheri, A. A., Civelek, A. C., Cupps, T. R., Kaplan, M. J., Malayeri, A. A., Merkel, P. A., Novakovich, E., Bluemke, D. A., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40379 · Cited by 352
Stone, J. R., Bruneval, P., Angelini, A., Bartoloni, G., Basso, C., Batoroeva, L., Buja, L. M., Butany, J., d'Amati, G., Fallon, J. T., et al. (2015) · Cardiovascular Pathology · doi:10.1016/j.carpath.2015.05.001 · Cited by 348
Self-citationNakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., & Nishimoto, N. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211878 · Cited by 344
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Seror, R., Baron, G., Hachulla, E., Debandt, M., Larroche, C., Puéchal, X., Maurier, F., de Wazieres, B., Quéméneur, T., Ravaud, P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203586 · Cited by 256
Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis
Saadoun, D., Garrido, M., Comarmond, C., Desbois, A. C., Domont, F., Savey, L., Terrier, B., Geri, G., Rosenzwajg, M., Klatzmann, D., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39037 · Cited by 253
Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
Izumi, K., Kuda, H., Ushikubo, M., Kuwana, M., Takeuchi, T., & Oshima, H. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000162 · Cited by 31
Metadata
- Authors
- Unizony, S., Arias‐Urdaneta, L., Miloslavsky, E., Arvikar, S., Khosroshahi, A., Keroack, B., Stone, J. R., & Stone, J. H.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2012-10-27
- Volume
- 64
- Issue
- 11
- Pages
- 1720-1729
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W1989068788
- Cited by
- 272
- References
- 44
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.